BR100 Decreased By (-1.08%)
BR30 Decreased By (-1.23%)
KSE100 Decreased By (-0.85%)
KSE30 Decreased By (-1.61%)
AGHA 6.11 Decreased By ▼ -0.07 (-1.13%)
BECO 4.12 Decreased By ▼ -0.11 (-2.6%)
BML 61.59 Decreased By ▼ -0.25 (-0.4%)
BOP 30.94 Decreased By ▼ -0.76 (-2.4%)
CNERGY 12.10 Increased By ▲ 0.04 (0.33%)
CSIL 5.65 Increased By ▲ 0.02 (0.36%)
FCCL 58.05 Decreased By ▼ -0.66 (-1.12%)
FFL 13.35 Decreased By ▼ -0.12 (-0.89%)
FNEL 1.16 Decreased By ▼ -0.01 (-0.85%)
KEL 6.11 Decreased By ▼ -0.03 (-0.49%)
KOSM 5.61 Decreased By ▼ -0.05 (-0.88%)
LOTCHEM 24.43 Decreased By ▼ -0.39 (-1.57%)
MLCF 100.04 Decreased By ▼ -2.05 (-2.01%)
NBP 175.92 Decreased By ▼ -3.74 (-2.08%)
NCPL 51.73 Increased By ▲ 1.68 (3.36%)
NPL 53.95 Increased By ▲ 1.05 (1.98%)
OGDC 312.89 Decreased By ▼ -3.35 (-1.06%)
PACE 9.22 Increased By ▲ 0.01 (0.11%)
PAEL 33.48 Decreased By ▼ -0.54 (-1.59%)
PIBTL 13.19 Decreased By ▼ -0.23 (-1.71%)
PPL 217.96 Decreased By ▼ -3.34 (-1.51%)
PRL 85.55 Increased By ▲ 0.95 (1.12%)
PTC 47.64 Decreased By ▼ -0.74 (-1.53%)
SSGC 22.60 Decreased By ▼ -0.34 (-1.48%)
TBL 9.16 Decreased By ▼ -0.14 (-1.51%)
TELE 7.15 Increased By ▲ 0.08 (1.13%)
TPL 25.48 Decreased By ▼ -0.38 (-1.47%)
TPLP 13.36 Increased By ▲ 0.25 (1.91%)
TREET 24.56 Decreased By ▼ -0.43 (-1.72%)
TRG 53.41 Decreased By ▼ -0.62 (-1.15%)
World

Oxford says COVID-19 vaccine 76pc effective for 3 months after one shot

  • AstraZeneca has welcomed the move, saying flexibility to extend the time between doses is the best strategy for the shot.
Published Updated
By

LONDON: The COVID-19 vaccine developed by Oxford University and AstraZeneca has 76pc efficacy against symptomatic infection for three months after a single dose, with greater effectiveness when a second is given later, a study showed on Tuesday.

Oxford University said the findings of the pre-print paper, which had not been peer-reviewed, supported Britain's decision to extend the interval between initial and booster doses of the shot to 12 weeks.

Britain has decided to give as many people as possible some protection by lengthening the amount of time between initial shots and booster shots of COVID-19 vaccines.

AstraZeneca has welcomed the move, saying flexibility to extend the time between doses is the best strategy for the shot.

The results, gathered from trials in Britain, Brazil and South Africa, indicated some protection was given after one shot and that immune responses were boosted with a longer interval to the second dose among participants aged 18 to 55 years.

"Vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 post vaccination was 76pc, and modelled analysis indicated that protection did not wane during this initial 3 month period," Oxford academics said.

The paper said that vaccine efficacy was 82.4pc with 12 or more weeks to the second dose, compared to 54.9pc for those where the booster was given under 6 weeks after the first dose.

Comments

Comments are closed for this article.